IFNA1 and cancer: Our data suggest that lenvatinib exhibits immunomodulatory activity by decreasing TAM numbers and that combined treatment with PD-1 blockade induces potent antitumor activities via the activation of IFN signaling pathways in cancer immune microenvironments.